First in cancer treatment: All patients recovered

Channel:
Subscribers:
30,300
Published on ● Video Link: https://www.youtube.com/watch?v=l20JuluuR3s



Duration: 2:10
2,128 views
39


First in cancer treatment: All patients recovered

New study published on cancer treatment in the USA. In a study on 18 rectal (large intestine) cancers, it was stated that all of the participants who were given a dose of medication every three weeks for six months recovered from their disease.

In a new study conducted in the USA, it was announced that 18 rectal cancer patients recovered completely with drug trials.

In the research published in the New England Journal of Medicine and supported by the pharmaceutical company GlaxoSmithKline, it was stated that cancer patients did not show any signs of the disease in physical examination, endoscopy, PET or MRI scans and they recovered completely.

D., co-author of the paper presented at the annual meeting of the American Society of Clinical Oncology and oncologist at Memorial Sloan Kettering Cancer Center. “There were so many tears of happiness,” Andrea Cercek said of the work.

EACH DOSAGE OF MEDICINE 184 THOUSAND TL

In the study, it was underlined that while a dose of medication was given to 18 rectal cancer patients once every three weeks, the treatment lasted for six months and each dose of medication cost 11 thousand dollars (approximately 184 thousand TL).

After six months of drug treatment, the patients were followed for 12 months, and it was reported that no cancer cells or symptoms were detected at the end of the process.

It was emphasized that the research has already been tried on a small group and will be carried out with larger groups in the future.

“IT HAS HAPPENED FOR THE FIRST TIME IN CANCER HISTORY”

The author of the article is Dr. from Memorial Sloan Kettering Cancer Center. Luis A. Diaz Jr. "I believe this is the first time in the history of cancer," he said, adding that he does not know of any other study in which a treatment completely eradicated cancer in all patients.

While it was stated that the drug called Dostarlimab was used in the study, it was reported that the drug under study unmasked the cancer cells and enabled the immune system to recognize and destroy them.




Other Videos By GOLAHURA


2022-06-08Own a Nintendo Switch? Hold off buying any new games until this week's Super Sale
2022-06-08Alien life breakthrough: NASA head CONFIRMS belief that 'extraterrestrials are out there'
2022-06-08The world is on the alert: Microplastic sleet fell on Antarctica for the first time
2022-06-08WWE 2K22's Third DLC Pack Calls Up The Hurricane, Stacy Keibler, And NXT Stars
2022-06-08New images from the biggest treasure in history
2022-06-07Modern Warfare 2 reveal trailer start time: How to watch first look at new Call of Duty
2022-06-07Scientists explained: The type of music that strengthens the brain's performance
2022-06-07Teamfight Tactics tips: Conquer free League of Legends spinoff after Dragonlands update
2022-06-07New photos from Gigi Hadid's Frankies Bikinis collection have been released.
2022-06-07Hollywood chases Johnny Depp's lawyer Camille Vasquez
2022-06-07First in cancer treatment: All patients recovered
2022-06-07Apple has its own upscaling tech now, MetalFX Upscaling
2022-06-07See Madden NFL 23's FieldSense In Action
2022-06-06PS Plus June 2022 God of War release date, time, free PS4, PS5 games, deals, FINAL warning
2022-06-06Minecraft Wild Update release time, date: When is Minecraft 1.19 out? Early patch notes
2022-06-06Diabetes drug leads to significant weight loss in obesity patients
2022-06-06Working 4 days a week trial started in UK workplaces
2022-06-06The world's first transparent submarine vehicle met with tourists in Vietnam
2022-06-062022 MTV Cinema and TV Awards found their owners
2022-06-06Mercedes to recall 1 million vehicles
2022-06-06Wales qualify for the World Cup after 64 years ( 05 / 06 / 2022 )



Tags:
Andrea Cercek said of the work.
First in cancer treatment: All patients recovered
D.
co-author of the paper presented at the annual meeting of the
American Society of Clinical Oncology
and oncologist at Memorial Sloan Kettering Cancer Center
The author of the article is Dr. from
Memorial Sloan Kettering Cancer Center. Luis A. Diaz Jr
In the research published in the New England Journal of Medicine
and supported by the pharmaceutical company GlaxoSmithKline
cancer patients